David Trinkley, MD
Internal Medicine · Rehoboth Beach, DENPI 1982764536
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Novo Nordisk at 25.9% of the total. Reporting peaked in 2019 at $2,506 and has fallen 63.2% since, to $921 in 2022. Among internal medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $13.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$413
- Lilly USA, LLC$353
- AstraZeneca$350
- Pfizer$350
- Johnson & Johnson$200
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,259100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,110 |
| GSK | 30 | $413 |
| Lilly USA, LLC | 32 | $353 |
| AstraZeneca | 23 | $350 |
| Pfizer | 28 | $350 |
| Johnson & Johnson | 15 | $200 |
| AbbVie(2 entities) | 12 | $199 |
| Boehringer Ingelheim | 10 | $189 |
| Merck | 17 | $157 |
| Amarin Pharma, Inc. | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $147 |
| Gilead | 6 | $140 |
| Amgen | 5 | $89 |
| Abbott | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Astellas Pharma US Inc | 2 | $38 |
| Bayer | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Novartis | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Medtronic | 1 | $12 |
How this compares
$4,279 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $158,356 |
| EliquisApixaban | 34 | $46,081 |
| JardianceEmpagliflozin | 38 | $43,909 |
| RybelsusSemaglutide | 23 | $42,958 |
| MounjaroTirzepatide | 34 | $42,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $33,854 |
| TrulicityDulaglutide | 16 | $29,752 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $20,598 |
| Rosuvastatin Calcium | 566 | $11,899 |
| JanuviaSitagliptin Phosphate | 15 | $10,931 |
| Praluent PenAlirocumab | 17 | $8,146 |
| Atorvastatin Calcium | 346 | $4,603 |
| Metoprolol Succinate | 124 | $2,939 |
| Levothyroxine Sodium | 258 | $2,487 |
| SynthroidLevothyroxine Sodium | 58 | $2,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,110 | $201,314113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $353 | $71,81450 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $413 | $54,45252 claims |
| PfizerEliquis | $350 | $46,08134 claims |
| Boehringer IngelheimJardiance | $189 | $43,90938 claims |
| MerckJanuvia | $157 | $10,93115 claims |
| AbbVieSynthroid | $199 | $2,45258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Rehoboth Beach
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
- Fadi DamouniMillsboro$17K
- Rene BadilloBear$16K
- Robert KopeckiWilmington$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.